Post-Traumatic Stress Disorder Therapy Market Overview

The report is titled as ‘Post-Traumatic Stress Disorder Therapy Market: Opportunity Analysis and Future Assessment 2020-2028’. An overview of conceptual frameworks, analytical approaches of the post-traumatic stress disorder therapy market is the main objective of the report, which further consists of the market opportunity and insights of the data involved in the making of the respective market. The post-traumatic stress disorder therapy market is expected to grow at a significant rate in the near future.

The global post traumatic stress disorder therapy market in 2020 is estimated for more than US$ 13,350.1 Mn and expected to reach a value of US$ 19,054.9 Mn by 2028 with a significant CAGR of 4.6%.

Post-Traumatic Stress Disorder Therapy Market Definition

Presently, antidepressants including SSRIs (Zoloft and Paxil) are among the first line of treatment for post-traumatic stress disorder therapy, cover a higher market share in comparison to other segments in 2017 around the globe, and expected to be the same for the next decade.

Also, the number of accidents and violence is increasing day by day which acting as a factor that drives the growth of the prevalence of diseases globally. The global post-traumatic stress disorder therapy market is expected to grow significantly over the forecast period.

Source: National Institute of Mental Health, 2018

Post-Traumatic Stress Disorder Therapy Market Dynamics

The rising prevalence of post-traumatic stress disorder therapy globally is a primary factor driving the growth of the global post-traumatic stress disorder therapy market. For instance, according to data published by the National Health of Mental illness, in January 2018, mental illness is common in the U.S.; nearly 46.6 Mn U.S. adults were affected by the mental disorders in the year 2017. The cases related to cross-border tensions and violence are increasing around the globe, and to control situations like this, defense forces are moved at the sights of such violence.

Owing to an increasing number of such cases the demand of post-traumatic stress disorder among defense forces for military troops and guards is expected to propel the demand for post-traumatic stress disorder therapy market globally.

In addition, the increasing importance of programs related to injured military personnel rehabilitation is acting as a major factor driving the growth of the market around the world. Moreover, an increase in the rate of road accidents mainly in emerging economies is fueling the global market.

However, side effects related to some specific drugs increasing negative publicity and various lawsuits, which are acting as a barrier in the growth of post-traumatic stress disorder around the globe. For instance, consumption of Zoloft and Paxil by pregnant women led to septal heart defects, miscarriage, delayed development, cranial defect, and persistent pulmonary hypertension (PPHN) which is hampering the growth of the global market.

Nevertheless, an increase in the investment towards research and development programs related to the betterment of mechanisms of these drugs are expected to create better mechanisms for safe therapeutics. Increasing initiatives by public and private organizations are creating a major trend for the post-traumatic stress disorder market around the globe.

Post-Traumatic Stress Disorder Therapy Market Segmentation

The global post-traumatic stress disorder therapy market is segmented on the basis of class of drugs and by region.

•    By Class of Drugs

    Antidepressants

    Anti-Anxiety Drugs

    Other Drug Classes (Alpha-1 & Alpha-2 Receptor Antagonists, Atypical Antipsychotics, and Anticonvulsants)

•    By Region:

    North America

    Europe

    Asia Pacific

    Latin America

    Middle East

    Africa

Post-Traumatic Stress Disorder Therapy Market Competitive Landscape

Some of the key participating players in global post-traumatic stress disorder therapy market are GlaxoSmithKlineplc, Pfizer, Inc., Neurocrine Biosciences, Inc., Novartis Pharmaceuticals Corp., Azevan Pharmaceuticals, Inc., and Baylor Research Institute.

Regional Segmentation

On the basis of region, the post-traumatic stress disorder therapy market is segmented into North America, Europe, Asia Pacific, Latin America, Middle East, and Africa.

MMC Overview on Post-Traumatic Stress Disorder Therapy Market Report

The non-identical approach of Meridian Market Consultants stands with conceptual methods backed up with the data analysis. The novel market understanding approach makes up the standard of the assessment results that give better opportunity for the customers to put their effort.

A research report on the Post-Traumatic Stress Disorder Therapy market by Meridian Market Consultants is an in-depth and extensive study of the market based on the necessary data crunching and statistical analysis. It provides a brief view of the dynamics flowing through the market, which includes the factors that supports market and the factors that are acting as impedance for the growth of the market.

Furthermore, the report includes the various trends and opportunities in the respective market in different regions for a better understanding of readers that helps to analyze the potential of the market.

Factors that are benchmarked while estimating the market

Various factors that are benchmarked while estimating the market growth includes (but not restricted to):

•    New product designs and launches

•    Current product compliance

•    Reimbursement

•    Concerns for use of Post-Traumatic Stress Disorder Therapy

•    Advantages of Post-Traumatic Stress Disorder Therapy

Actions taken by the manufacturer and respective regulatory authorities also impact the market growth of the segment. These factors are understood at regional level and in major countries globally for providing regional insights of the product segment in the report. This helps our clients to take informed decision.

A mix of top-down and bottom-up approach is followed to arrive and validate our market value estimations. For a product segment like wherein one/two manufacturer(s) dominates the market, it’s products sales, previous growth rates and market expansion plans are considered to generate market share in the global market.

1.    Global Post-Traumatic Stress Disorder Therapy Market Report Overview

1.1.    Introduction

1.2.    Report Description

1.3.    Methodology

2.    Global Post-Traumatic Stress Disorder Therapy Market Overview

2.1.    Introduction

2.1.1.    Market Definition

2.1.2.    Market Taxonomy

2.2.    Executive Summary

2.3.    Global Post-Traumatic Stress Disorder Therapy Market Snapshot

2.4.    Global Post-Traumatic Stress Disorder Therapy Market Size and Forecast, 2020–2028

2.4.1.    Introduction

2.4.2.    Market Value Forecast and Annual Growth Rate (AGR) Comparison (2020–2028)

2.5.    Global Post-Traumatic Stress Disorder Therapy Market Dynamics

2.5.1.    Drivers

2.5.2.    Restraints

2.5.3.    Opportunity

2.5.4.    Trends

2.6.    Key Regulations

2.7.    Porter’s Five Forces Model

3.    Global Post-Traumatic Stress Disorder Therapy Market, By Class of Drugs

3.1.    Introduction

3.1.1.    Annual Growth Rate Comparison, By Class of Drugs

3.1.2.    BPS Analysis, By Class of Drugs

3.2.    Market Revenue (US$Mn) Forecast, By Class of Drugs

3.2.1.    Antidepressants

3.2.2.    Anti-Anxiety Drugs

3.2.3.    Other Drug Classes (Alpha-1 & Alpha-2 Receptor Antagonists, Atypical Antipsychotics, and Anticonvulsants)

3.3.    Global Post-Traumatic Stress Disorder Therapy Market Attractiveness Index, By Class of Drugs

4.    Global Post-Traumatic Stress Disorder Therapy Market, By Region

4.1.    Introduction

4.1.1.    Annual Growth Rate Comparison, By Region

4.1.2.    BPS Analysis, By Region

4.2.    Market Revenue (US$Mn) Forecast, By Region

4.2.1.    North America

4.2.2.    Latin America

4.2.3.    Europe

4.2.4.    Asia Pacific

4.2.5.    Middle East

4.2.6.    Africa

4.3.    Global Post-Traumatic Stress Disorder Therapy Market Attractiveness Index, By Region

5.    North America Post-Traumatic Stress Disorder Therapy Market Analysis and Forecast, 2020–2028

5.1.    Introduction

5.1.1.    Annual Growth Rate Comparison, By Country

5.1.2.    BPS Analysis, By Country

5.2.    Market Revenue (US$Mn) Forecast, By Country

5.2.1.    U.S. Post-Traumatic Stress Disorder Therapy Market

5.2.2.    Canada Post-Traumatic Stress Disorder Therapy Market

5.3.    North America Post-Traumatic Stress Disorder Therapy Market, By Class of Drugs

5.3.1.    Antidepressants

5.3.2.    Anti-Anxiety Drugs

5.3.2.1.    Other Drug Classes (Alpha-1 & Alpha-2 Receptor Antagonists, Atypical Antipsychotics, and Anticonvulsants)

5.4.    North America Post-Traumatic Stress Disorder Therapy Market Attractiveness Index

5.4.1.    By Country

5.4.2.    By Class of Drugs

6.    Latin America Post-Traumatic Stress Disorder Therapy Market Analysis and Forecast, 2020–2028

6.1.    Introduction

6.1.1.    Annual Growth Rate Comparison, By Country

6.1.2.    BPS Analysis, By Country

6.2.    Market (US$Mn) Forecast, By Country

6.2.1.    Brazil Post-Traumatic Stress Disorder Therapy Market

6.2.2.    Mexico Post-Traumatic Stress Disorder Therapy Market

6.2.3.    Argentina Post-Traumatic Stress Disorder Therapy Market

6.2.4.    Rest of Latin America Post-Traumatic Stress Disorder Therapy Market

6.3.    Latin America Post-Traumatic Stress Disorder Therapy Market, By Class of Drugs

6.3.1.    Antidepressants

6.3.2.    Anti-Anxiety Drugs

6.3.3.    Other Drug Classes (Alpha-1 & Alpha-2 Receptor Antagonists, Atypical Antipsychotics, and Anticonvulsants)

6.4.    Latin America Post-Traumatic Stress Disorder Therapy Market Attractiveness Index

6.4.1.    By Country

6.4.2.    By Class of Drugs

7.    Europe Post-Traumatic Stress Disorder Therapy Market Analysis and Forecast, 2020–2028

7.1.    Introduction

7.1.1.    Annual Growth Rate Comparison, By Country

7.1.2.    BPS Analysis, By Country

7.2.    Market (US$Mn) Forecast, By Country

7.2.1.    U.K. Post-Traumatic Stress Disorder Therapy Market

7.2.2.    Germany Post-Traumatic Stress Disorder Therapy Market

7.2.3.    Italy Post-Traumatic Stress Disorder Therapy Market

7.2.4.    France Post-Traumatic Stress Disorder Therapy Market

7.2.5.    Spain Post-Traumatic Stress Disorder Therapy Market

7.2.6.    Russia Post-Traumatic Stress Disorder Therapy Market

7.2.7.    Poland Post-Traumatic Stress Disorder Therapy Market

7.2.8.    BENELUX Post-Traumatic Stress Disorder Therapy Market

7.2.9.    NORDIC Post-Traumatic Stress Disorder Therapy Market

7.2.10.    Rest of Europe Post-Traumatic Stress Disorder Therapy Market

7.3.    Europe Post-Traumatic Stress Disorder Therapy Market, By Class of Drugs

7.3.1.    Antidepressants

7.3.2.    Anti-Anxiety Drugs

7.3.3.    Other Drug Classes (Alpha-1 & Alpha-2 Receptor Antagonists, Atypical Antipsychotics, and Anticonvulsants)

7.4.    Europe Post-Traumatic Stress Disorder Therapy Market Attractiveness Index

7.4.1.    By Country

7.4.2.    By Class of Drugs

8.    Asia Pacific Post-Traumatic Stress Disorder Therapy Market Analysis and Forecast, 2020–2028

8.1.    Introduction

8.1.1.    Annual Growth Rate Comparison, By Country

8.1.2.    BPS Analysis, By Country

8.2.    Market (US$Mn) Forecast, By Country

8.2.1.    China Post-Traumatic Stress Disorder Therapy Market

8.2.2.    India Post-Traumatic Stress Disorder Therapy Market

8.2.3.    Japan Post-Traumatic Stress Disorder Therapy Market

8.2.4.    Australia and New Zealand Post-Traumatic Stress Disorder Therapy Market

8.2.5.    South Korea Post-Traumatic Stress Disorder Therapy Market

8.2.6.    ASEAN Post-Traumatic Stress Disorder Therapy Market

8.2.7.    Rest of Asia Pacific Post-Traumatic Stress Disorder Therapy Market

8.3.    Asia Pacific Post-Traumatic Stress Disorder Therapy Market, By Class of Drugs

8.3.1.    Antidepressants

8.3.2.    Anti-Anxiety Drugs

8.3.3.    Other Drug Classes (Alpha-1 & Alpha-2 Receptor Antagonists, Atypical Antipsychotics, and Anticonvulsants)

8.4.    Asia Pacific Post-Traumatic Stress Disorder Therapy Market Attractiveness Index

8.4.1.    By Country

8.4.2.    By Class of Drugs

9.    Middle East Post-Traumatic Stress Disorder Therapy Market, By Region

9.1.    Introduction

9.1.1.    Annual Growth Rate Comparison, By Country

9.1.2.    BPS Analysis, By Country

9.2.    Market (US$Mn) Forecast, By Country

9.2.1.    GCC Countries Post-Traumatic Stress Disorder Therapy Market

9.2.2.    Israel Post-Traumatic Stress Disorder Therapy Market

9.2.3.    Oman Post-Traumatic Stress Disorder Therapy Market

9.2.4.    Rest of Middle East Post-Traumatic Stress Disorder Therapy Market

9.3.    Middle East Post-Traumatic Stress Disorder Therapy Market, By Class of Drugs

9.3.1.    Antidepressants

9.3.2.    Anti-Anxiety Drugs

9.3.3.    Other Drug Classes (Alpha-1 & Alpha-2 Receptor Antagonists, Atypical Antipsychotics, and Anticonvulsants)

9.4.    Middle East Post-Traumatic Stress Disorder Therapy Market Attractiveness Index

9.4.1.    By Country

9.4.2.    By Class of Drugs

10.    Africa Post-Traumatic Stress Disorder Therapy Market, By Region

10.1.    Introduction

10.1.1.    Annual Growth Rate Comparison, By Country

10.1.2.    BPS Analysis, By Country

10.2.    Market (US$Mn) Forecast, By Country

10.2.1.    South Africa Post-Traumatic Stress Disorder Therapy Market

10.2.2.    Egypt Post-Traumatic Stress Disorder Therapy Market

10.2.3.    North Africa Post-Traumatic Stress Disorder Therapy Market

10.2.4.    Rest of Africa Post-Traumatic Stress Disorder Therapy Market

10.3.    Africa Post-Traumatic Stress Disorder Therapy Market, By Class of Drugs

10.3.1.    Antidepressants

10.3.2.    Anti-Anxiety Drugs

10.3.3.    Other Drug Classes (Alpha-1 & Alpha-2 Receptor Antagonists, Atypical Antipsychotics, and Anticonvulsants)

10.4.    Africa Post-Traumatic Stress Disorder Therapy Market Attractiveness Index

10.4.1.    By Country

10.4.2.    By Class of Drugs

11.    Recommendation

11.1.    Market Strategy

12.    Competitive Landscape

12.1.    Competition Dashboard

12.2.    List and Company Overview of Global Key Players

12.3.    Company Profiles

12.3.1.    GlaxoSmithKlineplc, Pfizer, Inc.

12.3.1.1.    Company Overview

12.3.1.2.    Financial Overview

12.3.1.3.    Product Portfolio

12.3.1.4.    Key Developments

12.3.1.5.    Business Strategies

12.3.2.    Neurocrine Biosciences, Inc.

12.3.3.    Novartis Pharmaceuticals Corp.

12.3.4.    Azevan Pharmaceuticals, Inc.

12.3.5.    Baylor Research Institute

13.    Acronyms